JP2004516295A5 - - Google Patents

Download PDF

Info

Publication number
JP2004516295A5
JP2004516295A5 JP2002551566A JP2002551566A JP2004516295A5 JP 2004516295 A5 JP2004516295 A5 JP 2004516295A5 JP 2002551566 A JP2002551566 A JP 2002551566A JP 2002551566 A JP2002551566 A JP 2002551566A JP 2004516295 A5 JP2004516295 A5 JP 2004516295A5
Authority
JP
Japan
Prior art keywords
ylmethyl
benzoxazol
dihydroisoxazol
piperidin
fluorobenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2002551566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2001/002277 external-priority patent/WO2002050070A2/en
Publication of JP2004516295A publication Critical patent/JP2004516295A/ja
Publication of JP2004516295A5 publication Critical patent/JP2004516295A5/ja
Abandoned legal-status Critical Current

Links

JP2002551566A 2000-12-21 2001-11-30 サブタイプ選択的なn−メチル−d−アスパラギン酸拮抗薬としてのピペリジン誘導体 Abandoned JP2004516295A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25783200P 2000-12-21 2000-12-21
PCT/IB2001/002277 WO2002050070A2 (en) 2000-12-21 2001-11-30 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists

Publications (2)

Publication Number Publication Date
JP2004516295A JP2004516295A (ja) 2004-06-03
JP2004516295A5 true JP2004516295A5 (enExample) 2005-06-23

Family

ID=22977943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002551566A Abandoned JP2004516295A (ja) 2000-12-21 2001-11-30 サブタイプ選択的なn−メチル−d−アスパラギン酸拮抗薬としてのピペリジン誘導体

Country Status (13)

Country Link
US (1) US6642256B2 (enExample)
EP (1) EP1345935A2 (enExample)
JP (1) JP2004516295A (enExample)
AU (1) AU2002223968A1 (enExample)
BR (1) BR0116311A (enExample)
CA (1) CA2436699A1 (enExample)
HN (1) HN2001000280A (enExample)
MX (1) MXPA03004652A (enExample)
PA (1) PA8535901A1 (enExample)
PE (1) PE20020882A1 (enExample)
TN (1) TNSN01175A1 (enExample)
UY (1) UY27081A1 (enExample)
WO (1) WO2002050070A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) * 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CA2537185A1 (en) 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
GT200600042A (es) * 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
JPWO2006137465A1 (ja) * 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
JP5573307B2 (ja) * 2010-03-31 2014-08-20 Jsr株式会社 感放射線性樹脂組成物、重合体及び化合物
CA2936749C (en) 2010-06-11 2019-07-09 Joshua R. Giguere Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2018033853A2 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN110662541B (zh) * 2017-03-12 2023-02-10 王晓冬 多环胺作为阿片受体调节剂
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
CN115135317A (zh) 2020-01-22 2022-09-30 西洛斯治疗有限公司 减少nmda拮抗剂的副作用
CN117466836A (zh) * 2023-11-14 2024-01-30 万华化学集团股份有限公司 一种合成烯丙基叔胺的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088062C (zh) * 1994-11-23 2002-07-24 纽罗根公司 某些4-氨基甲基-2-取代的咪唑衍生物2-氨基甲基-4-取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
DE19531321A1 (de) 1995-08-25 1997-02-27 Merck Patent Gmbh Piperidinylmethyloxazolidinone
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
DE19739332C1 (de) * 1997-09-09 1998-11-26 Merck Patent Gmbh Piperidinylmethyloxazolidinon-Derivat
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
AU2960599A (en) * 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
WO2000018763A2 (en) * 1998-09-29 2000-04-06 Neurogen Corporation 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands

Similar Documents

Publication Publication Date Title
JP2004516295A5 (enExample)
US9856247B2 (en) 4-methyl-dihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
US9926285B2 (en) Allosteric modulators of nicotinic acetylcholine receptors
JP2019077725A5 (enExample)
US11713312B2 (en) Substituted bicyclic compounds as farnesoid X receptor modulators
JP2006502134A5 (enExample)
JP2020516671A5 (enExample)
US20050043545A1 (en) 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
JP2012502006A5 (enExample)
JP2020512373A5 (enExample)
JP2008513515A5 (enExample)
JP2008513499A5 (enExample)
JP2007505091A5 (enExample)
AU782191B2 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
RU2008126398A (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpti)
JP2007516173A5 (enExample)
JP2015509510A5 (enExample)
JP2008500991A (ja) 医学的使用のためのcrth2レセプターリガンド
JP2009525275A (ja) 多環式1,2,3,4−テトラヒドロ−イソキノリン誘導体およびpparモジュレーターとしてのそれらを含む組成物
RU2008110949A (ru) Соединения и композиции-иммуносупрессанты
TW201038586A (en) Sulfonamide derivatives
KR20090024820A (ko) 인간 단백질 티로신 포스파타아제 억제제 및 이용 방법
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2006503081A5 (enExample)
WO2004101529A1 (ja) 含窒素複素環化合物およびその医薬用途